undisclosed E6AP inhibitor / Outrun Therapeutics - LARVOL DELTA

Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer… (PRNewswire) - "Outrun has selected an E6AP inhibitor strategy as the lead programme from its first-in-class therapeutic pipeline developed through the application of its proprietary XL discovery platform....The Company expects to announce a development candidate later this year....Programme has demonstrated strong in vitro and in vivo proof of mechanism, and is expected to enter the clinic in 2027."

New molecule • New trial • Head and Neck Cancer